

# Adam Gater

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2194832/publications.pdf>

Version: 2024-02-01

32  
papers

526  
citations

840776

11  
h-index

677142

22  
g-index

33  
all docs

33  
docs citations

33  
times ranked

785  
citing authors

#	ARTICLE	IF	CITATIONS
1	“Sometimes It’s Difficult to Have a Normal Life”: Results from a Qualitative Study Exploring Caregiver Burden in Schizophrenia. <i>Schizophrenia Research and Treatment</i> , 2014, 2014, 1-13.	1.5	66
2	The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical review. <i>BMC Public Health</i> , 2015, 15, 193.	2.9	57
3	Haemophilia B: impact on patients and economic burden of disease. <i>Thrombosis and Haemostasis</i> , 2011, 106, 398-404.	3.4	54
4	Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. <i>Leukemia Research</i> , 2012, 36, 817-825.	0.8	51
5	Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. <i>BMC Infectious Diseases</i> , 2014, 14, 402.	2.9	49
6	Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the zoster quality of life (ZQOL) study. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 92.	2.4	40
7	Assessing Asthma Symptoms in Adolescents and Adults: Qualitative Research Supporting Development of the Asthma Daily Symptom Diary. <i>Value in Health</i> , 2016, 19, 440-450.	0.3	25
8	Assessing the Impact of Caring for a Person with Schizophrenia: Development of the Schizophrenia Caregiver Questionnaire. <i>Patient</i> , 2015, 8, 507-520.	2.7	18
9	Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 13.	1.9	18
10	Patient-Centered Insights on Treatment Decision Making and Living with Acute Myeloid Leukemia and Other Hematologic Cancers. <i>Patient</i> , 2020, 13, 83-102.	2.7	15
11	Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD. <i>Dermatology and Therapy</i> , 2021, 11, 221-233.	3.0	12
12	An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial. <i>Advances in Therapy</i> , 2010, 27, 533-546.	2.9	11
13	Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer. <i>European Journal of Cancer Care</i> , 2019, 28, e12949.	1.5	11
14	The Potential Role of Individual-Level Benefit-Risk Assessment in Treatment Decision Making: A DIA Study Endpoints Community Workstream. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 630-638.	1.6	11
15	Understanding the Patient Experience of Severe, Recurrent, Bilateral Nasal Polyps: A Qualitative Interview Study in the United States and Germany. <i>Value in Health</i> , 2020, 23, 632-641.	0.3	11
16	Development of a conceptual model evaluating the humanistic and economic burden of Crohn’s disease: implications for patient-reported outcomes measurement and economic evaluation. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 643-656.	1.4	9
17	The feasibility of using electronic clinical outcome assessments in people with schizophrenia and their informal caregivers. <i>Patient Related Outcome Measures</i> , 2015, 6, 91.	1.2	8
18	Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade®). <i>Blood</i> , 2008, 112, 1307-1307.	1.4	8

#	ARTICLE	IF	CITATIONS
19	Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). <i>Advances in Therapy</i> , 2018, 35, 2186-2200.	2.9	7
20	Evaluation of the Content Validity and Cross-Cultural Validity of the Study Participant Feedback Questionnaire (SPFQ). <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1522-1533.	1.6	7
21	Assessing the Comparability of Paper and Electronic Versions of the EORTC QOL Module for Head and Neck Cancer: A Qualitative Study. <i>JMIR Cancer</i> , 2017, 3, e7.	2.4	7
22	Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study. <i>BMC Research Notes</i> , 2013, 6, 486.	1.4	5
23	Development and First Use of the Patient's Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit/Harm of Drugs Received During Clinical Studies. <i>Drug Safety</i> , 2020, 43, 119-134.	3.2	5
24	EVAPIL-R Scale: Continuous Development and Validation of a Tool to Assess Patient-Reported Tolerability of Different Contraceptive Methods in Longitudinal Studies. <i>Clinical Therapeutics</i> , 2014, 36, 638-647.e3.	2.5	4
25	Unique Challenges in Development, Psychometric Evaluation, and Interpretation of Daily and Event Diaries as Endpoints in Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 813-821.	1.6	4
26	Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in $\beta^2$ -Thalassemia Patients Previously Receiving Other Iron Chelation Therapies. <i>Blood</i> , 2009, 114, 2486-2486.	1.4	4
27	Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSDD): Measurement Properties of Novel Patient-Reported Symptom Measures. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1249-1259.	3.8	4
28	Patients' and clinicians' perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). <i>Health and Quality of Life Outcomes</i> , 2021, 19, 7.	2.4	2
29	Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family. <i>Blood</i> , 2019, 134, 3498-3498.	1.4	2
30	Qualitative evaluation of the symptoms and quality of life impacts of long-chain fatty acid oxidation disorders. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882110656.	3.2	1
31	A Patient-Centred Approach to Understanding the Trade-Offs Associated with Treatment Decision Making in Hematological Cancers with Short Life Expectancy. <i>Blood</i> , 2018, 132, 5899-5899.	1.4	0
32	Preliminary Exploration of Patient Perspectives on Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 5918-5918.	1.4	0